SBIR/STTR Research Award

FINE NEEDLE ASPIRATION BIOPSY(FNAB) NEEDLE DEVICE

Award identifier d3b8b7b5eaa864665375f1078891b3d779066dbcf4e7d0ffa4db6127844a7472Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$99,144

Program and phase

STTR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BIOINNOVATION, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

Fine Needle Aspiration Biopsies (FNAB) are widely performed due to their minimally invasive nature, low cost, and rapid turn around time for the diagnosis of various mass lesions such as cancer and infection. With increasingly, their use is expected to increase further mainly due to the escalating incidence of cancer. In the future, with the prevalence of in s- situ molecular techniques., FNAB will be the predominant and preferred method of tissue retrieval. Currently adapted hypodermic needles used for performing FNAB have many limitations including low reproducibility for adequate sampling A needle device that can overcome these drawbacks, therefore, has worldwide commercial potential. The present device is designed for a significantly higher and reproducible yield of diagnostic material even with minimum technical skill. This research is for finalizing he design to generate a prototype and prepare additional working models of this novel system. Tissue retrieval with these working models will be compared quantitatively and qualitatively with conventional hypodermic needs by performing experimental FNAB on beef liver. Depending on the results of this feasibility study, the molds of the final product will be made during phase II of the clinical trials are preparation towards commercialization (phase III). PROPOSED COMMERCIAL APPLICATIONS: This product has a worldwide market and could be easily marketed by many vendors. The average cost per unit would be $5 and is comparable to the cost of material currently used during FNAB procedure with modified hypodermic needle. Apart from the worldwide market, the potential market in United States alone should exceed $1,500,000 per year.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.